Arlington Capital Partners has made a majority growth investment in CBSET to enhance its preclinical research services and support significant capacity expansion.
Round Type
Venture
LexingtonBiotechnologyHealth CareInvestors
Description
Arlington Capital Partners has completed a majority growth investment in Concord Biomedical Sciences and Emerging Technologies, Inc. (CBSET), a Boston-area provider of translational research services. This investment aims to help CBSET scale its research platform through capacity expansion and strategic acquisitions. The partnership is designed to meet the rising demand for specialized preclinical research services in a complex regulatory environment.
Who to call at CBSET, and when
A new round usually means CBSET is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day CBSET raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at CBSET, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at CBSET. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment CBSET raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
CBSET raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.